What is the optimal management strategy for patients with type 2 diabetes mellitus undergoing haemodialysis?

Management of Type 2 Diabetes in Patients on Haemodialysis

For patients with type 2 diabetes on haemodialysis, avoid metformin and SGLT2 inhibitors entirely; use insulin as the primary therapy (preferably with continuous glucose monitoring), with DPP-4 inhibitors (linagliptin) or GLP-1 receptor agonists as alternative or adjunctive options based on cardiovascular comorbidities and tolerance. 1, 2

Medication Selection Algorithm

First-Line Therapy: Insulin

• Insulin is the preferred agent for patients on dialysis, as most oral agents have significant limitations at this level of kidney function 1
• Use basal-bolus regimens with insulin analogues rather than human insulin 3
• Initiate and titrate conservatively to avoid hypoglycemia, which is common in this population 2, 4
• Consider automated insulin delivery systems if available 5

Alternative/Adjunctive Agents

DPP-4 Inhibitors (Preferred oral agent):

• Linagliptin requires no dose adjustment and demonstrates lower glycemic variability compared to insulin alone 6
• Alogliptin: maximum 6.25 mg daily on dialysis 2
• Sitagliptin: maximum 25 mg daily on dialysis 2
• Saxagliptin: maximum 2.5 mg daily on dialysis 2

GLP-1 Receptor Agonists:

• Dulaglutide, liraglutide, and semaglutide require no dose adjustment and can be used on dialysis 2, 5
• Prioritize agents with documented cardiovascular benefits (liraglutide, semaglutide, dulaglutide) 1
• Exenatide once-weekly formulation should be avoided 2
• Lixisenatide is not recommended with eGFR <30 2

Medications to AVOID on Dialysis

Absolutely contraindicated:

• Metformin: Stop completely when eGFR <30 or on dialysis due to lactic acidosis risk 1, 2
• Glyburide: Not recommended at any stage of advanced CKD 2

Not recommended for initiation:

• SGLT2 inhibitors: While the guidelines state they can be "continued" if already established, initiation is not recommended on dialysis 1, 2. The glucose-lowering efficacy is minimal, and while cardiovascular/kidney benefits exist, the risk-benefit ratio shifts unfavorably in dialysis patients
• Ertugliflozin and empagliflozin: Not recommended with eGFR <45 2

Use with extreme caution:

• Sulfonylureas (glimepiride, glipizide): Initiate at very low doses (glimepiride 1 mg, glipizide 2.5 mg) and titrate slowly due to high hypoglycemia risk 2
• Acarbose and miglitol: Not recommended on dialysis 2

Glycemic Monitoring Strategy

Continuous Glucose Monitoring (CGM) is Superior to HbA1c

• HbA1c is unreliable in dialysis patients due to altered red blood cell turnover, anemia, and erythropoiesis-stimulating agents 5, 7, 8
• 68% of patients with HbA1c <8% failed to meet CGM targets in one study, indicating substantial underestimation of glycemic burden 8
• CGM reveals critical patterns: marked intradialytic glucose decline followed by incomplete post-dialysis recovery 7
• Use CGM metrics: Time in Range (TIR), Time Below Range (TBR), and glycemic variability 5, 7, 6, 8

Dialysis-Specific Glycemic Patterns

• Mean glucose levels are 13 mg/dL lower on dialysis days compared to non-dialysis days 8
• Nocturnal glucose levels tend to be lower in both dialysis and non-dialysis periods 6
• Hyperglycemia is the predominant pattern, not hypoglycemia, despite the intradialytic glucose decline 7

Critical Risk Management

Hypoglycemia Prevention

• 56.6% of dialysis patients with diabetes experience hypoglycemic episodes 4
• Each additional year on hemodialysis increases hypoglycemia odds by 30% 4
• Unadjusted insulin regimens triple the hypoglycemia risk (OR=3.0) 4
• Adjust insulin doses on dialysis days vs. non-dialysis days based on CGM patterns
• Time meals appropriately around dialysis sessions 9, 10

Hospitalization Risk Factors

• 65.3% of patients require hospitalization after starting HD, averaging 3.9 admissions 4
• Each extra year on HD increases hospitalization odds by 50% 4
• History of hypoglycemia increases hospitalization odds 3.4-fold 4
• Higher hemoglobin reduces hospitalization risk by 30% per 1 g/dL increase 4
• Higher serum calcium reduces hospitalization risk by 70% per 1 mg/dL increase 4

Multidisciplinary Care Requirements

Essential team coordination:

• Maintain active collaboration between nephrology and endocrinology teams 9, 10
• Avoid the assumption that "the other team is managing diabetes" 9
• Regular foot care assessment (high-risk population) 9
• Dietary support with renal-specific modifications 9

Monitoring schedule:

• CGM continuously if available 5, 7, 6, 8
• If using HbA1c, recognize its limitations and supplement with frequent glucose monitoring 8
• Monitor hemoglobin and correct anemia aggressively 4
• Monitor and optimize serum calcium and mineral metabolism 4

Lifestyle Modifications

• Encourage physical activity appropriate to cardiovascular tolerance and fall risk 1
• Avoid sedentary behavior 1
• Consider weight loss advice for patients with eGFR ≥30 (less applicable once on dialysis) 1

Common Pitfalls to Avoid

1. Continuing metformin on dialysis - absolute contraindication
2. Relying solely on HbA1c - systematically underestimates glycemic burden
3. Using the same insulin doses on dialysis and non-dialysis days - triples hypoglycemia risk
4. Initiating SGLT2 inhibitors - no role in dialysis initiation
5. Assuming diabetes care is being provided by the other specialty - leads to care gaps
6. Ignoring anemia and mineral metabolism - directly impacts hospitalization risk